Articles related to ADVERSE EVENTS

Discover how STRIDE is setting new benchmarks in the treatment of unresectable hepatocellular carcinoma, offering both improved survival rates and a tolerable safety profile.

New reports and studies are raising concerns about the gastrointestinal safety of semaglutide-containing medications; clinicians are advised to exercise caution and monitor patients for symptoms of gastroparesis.

Understanding the ocular side effects of targeted cancer therapies is crucial. Early monitoring and interdisciplinary communication can significantly impact treatment outcomes.

This retrospective cohort study provides evidence that the risk profiles for in-hospital adverse events are similar among haloperidol and atypical antipsychotics in older patients with postoperative delirium.

New research indicates that maternal hemoglobin levels can significantly impact both maternal and neonatal health outcomes, suggesting a need for revised antenatal care guidelines.

A recent study found that patients who used proton pump inhibitors (PPIs) for more than 4.4 years had a 33% higher risk of developing dementia during the follow-up period.